Table Of Content

SUBJECT INDEX: VOLUME 45 (2005) In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An “L” in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an “E” in parentheses indicates that the subject was discussed in an editorial; a “/” between numbers indicates on what page the correction for the subject entry appears. In Volume 45 (2005), Number One (January) contains pages 1-126; Number 2 (February), pages 127-286; Number 3 (March), pages 287-458; Number 4 (April), pages 459-650; Number 5 (May), pages 651-824; Number 6 (June), pages 825-1046; Number 7 (July), pages 1047-1240; Number 8 (August), pages 1241-1402; Number 9 (September), pages 1403-1546; Number 10 (October), pages 1547-1694; Number 11 (November), pages 1695-1830; and Number 12 (December), pages 1831-2008. Allogeneic blood transfusion. See Blood transfusion, allogeneic AABB Research Foundation grants Allogeneic platelet gels, frozen-and-thawed AB/D antigens, masking by pegylation ................cccssssseseseseseseseeenensees 374 Alloimmune refractoriness, prevention Abdominal attacks, in hereditary angioedema Alloimmune thrombocytopenic syndromes ABO blood group Alloimmunization PND sijsictininriaeninnanicninvensnniennsiicismntinnaiinamenaionniie 359, 1331 1554, 1561 anti-A/B quantification anti-Ku cis-AB allele fetomaternal 550, 1487, 1791, 1799 delayed PLT engraftment Max* ... discrepancy, by usurpation of identity genotyping discrepancy AMD3100 .... influence of differences in PBPCT American Red Cross SE, secitniiesissninnenjesniiiiiviannincniiiascanctniepananiiiildaseniviicntle 50, 645(L) Amicus blood cell separators O alleles Amicus Crecendo plateletpheresis device te RIE aiicisnissterinncstenievineieninsncseciminininniiactonsininincnnisauss Ty Oe [IFIs sitashisnsicsiaseniiicicaciionennnriibininieneiaitiniasmaaicantpmenindatiidiaiiestaliihdeatateeinvdlaaia 1735 reverse typing problems. ................0-..ccsecscsssssssesseessoseseosecsssesorsees 1331 Amotosalen secretor locus FFP treatment tetragametic chimerism HTLV-I and HTLV-II inactivation ABO gene mutation Leischmania inactivation ABO glycosyltransferase neoantigenicity, absence of ABO mismatch photodegradation measurement allogeneic HPCT PLT Concentrate treatMeNt ..........-cc-ccecceereeeeseeeeseneees 580, 1443, 1864 patient identification error Amt/MEP family ABO transferase, N-terminal domain Amyloidosis, PBPC mobilization and collection Absorption-elution techniques Anemia Additive solutions, platelet chemotherapy-induced Adhesion of hematopoietic graft chronic disease Administration from fetomaternal hemorrhage ... policies for new cellular therapies hemolytic transfusion medicine plan ... predonation screening - Angioedema, C1 inhibitor concentrate for . 1774 Adsorptions, autologous with PEG .. Animal models 1, 2S:109, 1899 Adverse events Annexin binding. .... . anti-CD36 isoantibody Antenatal screening 1945 from blood donation, estimating probability of RAITT TIA GE... cecerrcriececmtmncereiniveniiisinionnaiaiiiitiaas 56 photochemically-treated PLTs Anti-B19 detection transfusion-associated pulmonary Antibiotic therapy sequelae Antibodies. See also specific antibodies Advia 120 historical aspects of African Americans neutrophil-reactive D antigen 1547(E) PLT-reactive donor reactions 1398(L) RBC-reactive Age of donor screening probability of reaction and $-303 RBC WPM formation in RBC components Anti-CD36 Agglutination, in blood group typing Anticoagulants Agonists Anti-Cr’ .. Albumin Anti-D for fluid resuscitation vs. saline ................. : affinity polymerized alloimmunization . 1554, 1561 ALL, chemotherapy-induced apoptosis... immune response .... Alleles immunization Anti-Di® Anti-D immunization 453(L), 1581 POP ccncessovscseceoninnvnsesicinnnintinnsaennnasenieinemnancsnsnsssnamaneanisneinestitiviit 539 Antigens. See also specific antigens SSID sisastenssnctnsencensnien eseeniitenteiciieninaiiidaenniaantincglienanneninnial 50, 645(L) high-prevalence historical aspects RHD blood group variety Anti-HCV Alloantibodies Ramee occcececenseeneccsspesevennvennnyrpnanaiestnevssnenmeneccenensennsaennianiente 539 Alloantigens Anti-HNA- Ic, neonatal alloimmune neutropenia HPA SNP typing Anti-HPA-la 1165, 1945 low-frequency Anti- HPA-9bw Volume 45, December 2005 TRANSFUSION 1997 SUBJECT INDEX Anti-Jk’, naturally occurring ... .. 1043(L) visual inspection of blood units .... West Nile virus epidemic of 2003 experience Anti-Ku Blood cell preparations/ products. See also specific blood cell preparations/products Antithrombin III, in twice-frozen plasm parvovirus B19 contamination WBC destruction in Apoptosis, chemotherapy-induced Blood cell separators, quality control indicator .... Arab blood donors Blood collection, in United States Arachidonic acid .... Blood culture systems 1138, 1201. See also BacT/ALERT Arteriovenous fistula, following needle puncture for culture system blood donation Blood donation Arthroplasty, postoperative infection .... allogeneic, postoperative infection and AS.TEC204 .. autologous 103, 737 Canadian student ATP-to-ADP ratio crisis in + 128(E) Autoadsorptions, polyethylene glycol CI TE III, osssencscssinicrntninitcimncsiniorennnnninnimaimianiin 945 Autoimmune disease serial, for intrauterine transfusions .. 1791 transcription-mediated assay 1988 mixed-type hemolytic whole-blood -. 1957 phage display studies Blood donation screening. See Predonation screening Autologous chimerism Blood donation site, predicting donor arrival Automated systems Blood donors. See Donors buffy coat-derived pooled concentrates Blood group typing cell processing devices agglutination in culture system DNA microarray ... for donor history interviewing microarray platelet concentrate preparation .... mixed-field agglutination reaction PLT culture bottles problems, nondeletional ABO*O alleles and quality of plasma collections Blood irradiator dosimetry Blood outgrowth endothelial cells . Blood services network w- 48:206 Babesia microti, in blood donors Blood shortages, alleviating BacT/ALERT culture system Blood storage. See Storage plastic culture bottles Blood substitutes. See specific blood substitutes for PLTs ... Blood suppliers 4S:206 vs. PCR assay Blood supply chain 4S8:224 vs. Scansystem method Blood transfusion, allogeneic BACTEC 9240 blood culture system Be ION -asscinvninessaicseniorenpncendintiviniataniscimasnamveiavelitinictitaiclinaiai 956 Bacteremia RBC trigger, in critically ill patients Bacteria detection, in platelet concentrates . safety Bacterial contamination in United States cord blood universal leukoreduction of pooled PLT concentrates WBC transfer during Staphylococcus epidermidis ..............csesecesesesseesesssssscscssssensessenceees 927 Blood transfusion, autologous Bacterial detection Blood units, visual inspection of culture-based systems .... 984. See also BacT/ALERT culture system Blood utilization review 4S:159S enhanced PLT Blood volume, preoperative estimation as: extended platelet storage .... Bluetongue virus inactivation pH meter screening... pbeprnbstavnenaaecnasesnctets 514, 1374, 1845 Body weight, probability of donor reaction and _.. prestorage pooled PLTs .... we 904 Bone marrow HPC harvest, bacterial contamination ... in PRP PLTs 1275 Bone marrow transplantation, autologous I is icdtesc is ocaccitinantiiineunoasanebeqnscsacasnanbesstinanbinsie 265 Book reviews Bacterial virulence factor .... wwe 274 Immune Hemolytic anemias. ... BANG polymer gels .. 1658 Textbook of Hemophilia B-cell superantigen panabbiebicnhinunincenneeannbeinsit 274 Transfusion Therapy: Clinical Principles and B19 DNA Practice (Mintz) BeadChip analysis B phenotype, weak Bellovac-ABT autologous blood transfusion system ... Brazilian blood donors, first-time . B-glycosyltransferase enzyme Bronchoscopy Bicarbonate, bacterial inhibition Buffy coat-pooled platelets Bioterror agents, donor screening for automated systems 743 Birth weight preparation ... 634 Bleeding BVDV, viral inactivation ‘ 580 hemophilia clinical trial endpoints massive, cardiac surgery mortality and prediction during invasive diagnostic procedures Canada prevention, off-label rFVIla use PLT preparation rF-Vila therapy in cardiac surgery student blood donation .... Blood banks WNYV in blood donors blood transfusion safety .- 48:159 Cardiac surgery patients ISBT 128 labeling standard... .-. 1054(E), 1111 leukoreduced RBCs for on-call physician's experiences ..................c.cscscssoscssssssesereeseeseerereeee 3D 1998 TRANSFUSION Volume 45, December 2005 SUBJECT INDEX recombinant factor Vila in donors, CMV testing S-303 RBCs for filter Cardiogenic shock hematopoietic progenitor cell content Catalase postthaw/postwash Caucasian blood donor population, D antigen .. 1547(E) processing CB unit, volume reduction SCID-repopulating activ screening CD34+ cells . --. 248, 885, 1192 stem cell quality collection after imatinib mesylate in CML ...........c.ccccceeeeeeeeeeeeees 1214 storage in cord blood 613, 856, 1828(L) Cord blood banks e867 count, cord blood unit quality and 189, 455-456(L) quality control 826, 832 low yield on ae standard operating procedures mobilization and collection — Cord blood transplantation prefreezing vs. thawed content 116-117(L), 117-118(L) allogenic adult .- 829(E), 1027 ST NN UIIIIII cxisocnssittscecnnpitnionesiinstensebiibieebsietetiommnmansociatetsotbetianaatiinanios 366 quality, variables in 189, 826(E) CD36 isoantibody Cord blood units CD34 protein ... quality CD4+ T cells selection for storage Cell destruction marker .... Corrected count increment, posttransfusion Cell lines, allele-specific .... Corticoid stimulation, of PMN donors Cell separators, quality control indicator Cost allocation method, for hospital-based clinical Cellular therapies 48:241. See also specific cellular therapies laboratories administrative policies Cost-effectiveness analysis 4S:159 anti-HPA-1la antenatal screening Central vein cannulation .. microbial surveillance Centrifugation leukapheresis PF4 ELISA CFUs Cost estimates, HCV transfusion lookback program Chemotherapy-induced anemia Council on Research and Development (CORD) Chemotherapy-induced apoptosis Creutzfeldt-Jakob disease Children CR1 inhibitors rHuEPO facilitation of autologous blood Critically ill patients donation allogeneic RBC transfusion trigger WBC-reduced split apheresis PLT concentrates erythropoietin for Chimerism, tetragametic fluid resuscitation Chinese blood donors Cromer antigens Cholesterol, WPM formation in RBC components CRI structure-function Chronic disease, anemia Cryopreservation CIDP, idiopathic automated washing technique C1 inhibitor concentrate CD34+ cell viability evaluation Circulatory overload closed-system blood culture of BOECs Clinical trial endpoints cord blood fluid resuscitation for traumatic injuries hematopoietic progenitor cells. .... hemophilia TIER ITED ececteninrterinstnrseenierinsesscmmentenesenienmnncnieinenenasisanionl: transfusion requirements ... RBC recovery 822(L), 823(L) Clinical trials, regulatory perspectives standard procedures Closed-systems CS-3000 Plus blood cell separator BOEC blood culture Ce IIE | escsscrererssensitninesiscininbtanseencememenmnieneneipeneaiiaiatintigaiaaiaiains Ge RBC glycerolization CytoMate Clostridial bacteremia, secondary hemolysis Clotting factors. See Coagulation factors CLX containers CO ccccnees 16, 1214 D antigens CHY .... .. 228, 580, 1722 DEI Coagulation factors .... 1453, 1829(L). See also specific coagulation factors weak congenital deficiencies ... 1362 in cryosupernatant -. 1453 Data envelope analysis storage effects - 1342 dCE haplotype . Coagulation test, abnormal without procedural bleeding 1413 DCLHb COBAS AmpliScreen HBV test - 1247 DDAVP COBE Spectra LRS_ .. 788 Decay-accelerating factor COBLT Study 2, 856, 1027 DEHP exposure Colony-forming cells, content in cord blood 613 SSIUTIO -icsisasecieseipeahdenaseellabadasiieanianiieaidanindaticagin a oe Communication, e-mail donor recruitment program 1957 Delayed hemolytic transfusion reaction, massive hemolysis with Compatibility testing, pretransfusion ................cccccceeeeeeeneeeeeee 252100 pancreatitis 1691(L) Complement receptor | Delayed hemolytic transfusion reactions . 1925 Complement system, therapeutics ‘ DELFIA analysis GIG IIILS .c otuicstsivernsvtsnninnicessinatinnnticiacnitneneiaabsnchssivsibestannagnesnunnennneneanininiiunetien 788 Delivery method, cord blood characterization Cord blood D. phenoype CD34+ cell content, newborn sex and 1828(L) Dendritic cells CMV PCR testing .... .-. 1722 Dermatobia hominis .... collection Dexamethasone, with lenograstim cryopreservation DHBY, viral inactivation ... donor recruitment DHPLC Volume 45, December 20°5 TRANSFUSION 1999 SUBJECT INDEX Diabetes Erythropoietin Diagnostic test systems, adaptations for critically ill patients Dipyridamole rHuEPO facilitation of autologous blood donation 820(L), 821(L) DNA analysis, high-throughput Ethical dilemmas 1697(E) DNA-based assays. See Nucleic acid testing Ethnicity DNA microarray hybridization cord blood . DNA sequencing D antigen .. Documentation, cord blood .. Dodecapeptide HPA-15 alleles para-Bombay phenotype Dombrock blood group system .. RHD alleles Donation intentions, of nondonors ... Rh locus variability Donor history interview, automated system for whole-blood donors reactions Donor-recipient MHC disparity .............ccecssessessseeesessesestesesenseceereenenes 301 European multicenter study Donor-recipient repository 1051(E), 1073 European populations 1183, 1325 Donor recruitment EVA plastic bags 822(L), 823(L) cord blood mononuclear cell Fatigue, donor Donors. See also Predonation screening FcyR-mediated phagocytosis adverse reactions Febrile nonhemolytic transfusion reactions, pathogenesis RN III IIIT asc s.ces ites nscnsivscermnnsissenetbanssantbnsetcieaneenstionietaiions 580 Babesia microti in Femoral angiography deferral Ferritin, compensating for iron loss in regular donors 1236(L) first-time Fetal and neonatal alloimmune thrombocytopenia G-CSF stimulated * low-frequency HPAS and. ..........c.scecceeeeseeeeeereeeeeeseee 353, 366, 1799 with indeterminate HIV status, allogeneic HPCT ... .- 819(L) research infection detection rates unexpected Glanzmann thrombasthenia carriers . lack of correlation of HBV DNA with HBsAg . . 1039(L) Fetal DNA, cell-free leukapheresis, [V magnesium supplementation . Fetal hemoglobin, signaled expre: = myiasis in Fetal RBC survival 1985(L) predicting arrival of 803, 1453 rapid identification of iron deficiency iM ................cccceceeeseeeeeeeeees for minimally elevated INRs 1234(L) reactions PCT-treated, for congenital coagulation factor regular, compensating for iron loss in deficiencies risk profiles production quality I Sicocasicastrestconcienietisitiacecieieesinkssetonon onsnssostsaneaecosabaassvcuvbesibtoni 945 protein C, protein S and antithrombin III in 281(L) Toxoplasma gondii antibodies ..............0.c.ccccesseeeeeseseneeeeeee 281-282(L) storage 1829(L) variables, cord blood unit quality and TRALI risk reduction DOSE-MAP film dosimetry system Dose-response relationship, lenograstim plus dexamethasone Fibrinogen D phenotype, weak, detection of Fibrinogen y-chain dodecapeptide D+ population, RHD alleles Fibrin sealants Dry-heat process Fibronectin Filtration, WBC. See Leukoreduction NII. scinstecenitcssaciescesiicdinasbiniiceesniphveneniceimeesiccnpnevibintnabeiel 504, 539, 1496 of CD34+ cell viability ............. ie - 1208 . 48:172S CD109 PLT surface expression .- 366 HLA alloimmunization detection in PLT transfusion 1399(L) 1816, 1965 mitochondrial function in PLTs Rh, Syndrome WBC destruction in blood products anti-D affinity Fluid resuscitation Fluorescence E-mail donor communication program Freeze-drying process, fibrinogen Embryonic stem cell detection Freeze-thaw-wash process 1391, 1890, 1909 Endoscopic procedures Freeze-thaw-wash recovery 822(L), 823(L) Endothelial cells Freezing medium, cord blood cryopreservation activation, in TRALI pathogenesis Frequency of Agents Communicable by Transmission blood outgrowth Study (FACTS) progenitor, source of ... Frozen plasma, West Nile virus detection in Endotoxemia Engraftment FUT] allele G-CSF-mobilized PBPCs Epitope mapping Epstein-Barr virus Eptifibatide Erythrocyte membrane-associated protein (ERMAP) Erythroid engraftment Erythropoiesis Erythropoietic protoporphyria 2000 TRANSFUSION Volume 45, December 2005 SUBJECT INDEX engraftment DUCES, GODT icc ccectccncvenicessinitenssntevirtaviivasbnnvesessensssesasecnnenaiics 562 for PMN collection 1697(E) Hematologic malignancies, exposure to parvovirus B19 Gene array 654 Hematopoietic reconstitution Gene knockdown. .... cents ae Hematopoietic stem cells Genotyping seeseseeeee 990, 1473 Hemolysis D.. . 1568 CD34+ cell viability after cryopreservation HAV . w: 1097 gross high-throughput RBC and PLT antigen 660 hyperhemolysis syndrome Geographic distribution of donors, weak D 1568 massive, with pancreatitis Germany -- 1097 during PMT Glanzmann thrombasthenia carriers . 550 reduction in stored RBC concentrate Globin-chain switching . 1229 secondary to clostridial bacteremia Glucocorticoid stimulation, of neutrophil donors 1697(E) Hemolytic anemia Glucose consumption, PLT storage and 1349, 1504, 1750 Hemolytic disease of newborn «+ 975, 1791 Glycerolization, closed-system Hemolytic transfusion reactions Glycolysis reduction, PLT storage .... 1925 Glycophingolipid anti-Jk* weer 956 Glycoproteins mimicking -. 1291 Glycosyltransferases .... Hemophilia, clinical trial endpoints 2 Hemorrhage, fetomaternal .... wwe 539 Granulocyte donors, posterior subcapsular Hemostasis 1453 cataract risk 1697(E), 1701 clinical trial regulations . 18:14 Granulocyte storage . 1876 effective therapies we. 1404 Granulocyte transfusion hemophilia clinical trial endpoints 18:2 Growth factor release, by plateletpheresis Hemostasis-enhancing agents 18:2 Guillain-Barre syndrome Hepatocellular carcinoma, SEN-V -- 1084 GVHD Hereditary angioedema, C1 inhibitor concentrate for ABO mismatch HES sedimentation . HPA mismatch Hip replacement surgery, preoperative autologous donation History, of transfusion medicine Haemonetics APc 215 HIV HAV comparison of detection methods donor screening donor deferral genotype indeterminate status of donor, allogeneic HPCT magnetic-bead RNA extraction prevalence, incidence, residual risk in first-time PCR assays .... blood donors travel-related prevalence vs. incidence transfusion-transmitted, in Italy donor screening .. EF latency noninvasive screening Procleix ultrio assay polymerized bovine transcription-mediated assay rapid identification in reticulocytes transfusion-transmitted risk HBOC-201 infusion, for Jehovah's Witness a viral inactivation III siciscisputnivesiisennasarubensitanisinsicepeiciesivintaiipianisunbspiatiisighitisinitieininia ‘ HLA- 1a, quantification HBsAg, lack of correlation with HBV DNA in donors 1039(L) HLA alloimmunization, detection by flow cytometry 1399(L) HLA antibodies . 761, 1925 DNA in donors, lack of correlation with HBsAg 1039(L) HLA antigens . 761, 1165 donor deferral HLA-DRB1 alleles 1106, 1247, 1988 HLA match, PBPC transplantation and pooled DNA testing... . 1242(B) HLA typing, cord blood prevalence vs. incidence Hospital Procleix ultrio assay clinical laboratories, cost allocation method risk, transfusion history and .. transfusion, cellular processes and . 48:159S transfusion-transmitted, in Italy .. 654 viral inactivation HPA-1 HPA-3 comparison of detection methods .... HPA-15 alloantibodies detection 1518, 1965 HPA-9b (Max") donor deferral 1593 HPA microarray early infection dynamics .... HPA typing 1040(L) HPC-A ... prevalence vs. incidence . .. 1089 HPCs .. . 1899, 1917 Procleix ultrio assay bacterial contamination. ... risk, transfusion history and cord blood 613, 622, 856 transcription-mediated assay thawed, DMSO in transfusion lookback program HPCT, allogeneic transfusion-transmitted risk .... ABO mismatch . 643(L), 779 viral inactivation donor with indeterminate HIV status 819(L) HCV EIA, signal-to-cutoff ratios recipients, trigger for prophylactic PLT transfusion Health economics ROPE, ID creseccremrstennreniecnnennnneinisiiannitiaainiencnnsistndinibivitionanints Tae Helper T-cell response, alloreactive HPLC assay Volume 45, December 2005 TRANSFUSION 2001 SUBJECT INDEX H12-polyALB Lanthanide fluoroimmunoassay, enhanced Large-volume leukapheresis Human adenovirus-5, viral inactivation Leishmania inactivation Human platelet antigens. See HPA Lenograstim. See G-CSF Hybridoma, Dombrock blood group Leukapheresis Hyperhemolysis syndrome Leukodepletion Hyperimmune globulins Leukoreduction Epstein-Barr virus removal ee 21, 1839 III ciiscissesceusccsasisasacecnenstensnsonvesoiesesbinsonseséhsesbiigeshctateonsaimsaconssichhen 56 hemolysis reduction in stored RBC concentrate. ............:.s0cee0+00+ 90 IgG fragments, in liquid [VIG IIIT IIE oncinssenisonssssnncnintesrschntitincenioniehdistieesanbreieseiinnesshinstieds 1523 IgM, cytotoxic activity against PMNs 115-116(L) prestorage pooled PLTs NINE sclsm nsscsclnsabiosiantenaSisbenssbactemvesbaannensbetstesusseuusensseicabruantiien 960 universal Imatinib mesylate Light Cycler RT-PCR infectivity assay 1011, 1097 Immigrants, parentage analysis III cissenicosascxcninesissnvesscensnisennhenincbberseenntiiashniteisanntnionvateinstinei 315 Immune cytopenias Line-related infections Immune pancytopenia, oxaliplatin-induced Liver biopsy Immune responses Liver disease, SEN-V Immune thrombocytopenia Liver transplantation, living donor Immune tolerance, inducing across MHC barrier Living-donor liver transplantation Immunoblotting, Dombrock glycoprotein Luke antigen Immunofluorescence assay Lymphocyte subset content, cord blood Immunomodulation, transfusion-related Incidence, transfusion-transmissible viral infections M Inclusion body myositis MagNaA Pure-COBAS AmpliScreen method Indirect hemagglutination test Magnesium, during leukapheresis Infection. See also Transfusion-transmitted infections Magnetic bead technology line-related MAIGA assay .... postoperative ae MAIPA assay Infectious agents, donor-recipient repository . .. 1051(E), 1073 MAIRA assay ‘ Information technology Major histocompatibility complex 181, 301 1234(L), 1413, 1435 Maleimidophenylppolyethlene glycol ...............cccsseseseeesessseneesesesesrseeeees 374 Integrins 1165, 1192 Male-to-male sexual experience, on donor risk profile . .-. 404 INTERCEPT Blood System 1443, 1464, 1610 Maternal antibodies, anti- HNA-Ic Interferon therapy, SEN-V Maternal blood, fetal RBC survival 1985(L) Intraoperative blood loss, living-donor liver transplantation IRIE SII esses sscsssnsinecinissisoeanipsntinnoenntiannssiosctasesteestnnees a Intrauterine transfusions Maternal plasma, cell-free fetal DNA in Invasive diagnostic procedures, predicting bleeding Maternofetal alloimmunization ..............:.cccceseeeeeeeeeeeeeee 550, 1487, 1791 during Mathematical algorithm, for preoperative blood volume I 2 scisirecsconssennasd-sseseneecnibsluiicashubasboeieniceseetbeteevicosiextbials 927, 1768 I 2ac sibscocxccccasicicapeecesascninisnncelibiiodaeosibasbucasveatestunienintnetebnbedion 562 Iron deficiency, rapid identification in blood donors. ................see 5 Max® (Anti- HPA-9bw) Iron loss, compensating for in regular donors 1236(L) MCS+ LN9000 blood cell separator ISBT 128 Code 1054(E), 1111 MCS Plus plateletpheresis device Isoagglutinins 1331, 1676 Medical coordinating center Isoantibody .... Megakaryocyte-erythroid progenitor Cells .............:.ccsseeeseseeeeseeseneneeeeees 969 isohemagglutinins .. .. 779 Metabolic suppression, for PLT storage ............:csccsesseseseeesesenteeeeesees 214 Isosulfan blue dye ... ; . 1047 Mexican blood donors, Toxoplasma gondii antibodies 281-282(L) Italy, transfusion-transmitted infections in . MHC antigens - 1601, 1640 Microarray-based genotyping . 654 Microbial contamination, HPC grafts . 874 Microbiai surveillance, cost-effectiveness . .. 874 JAHK (RH53) antigen Microchimerism, posttransfusion 1280 Japanese woman, secondary anti-D immunization Migration of hematopoietic graft . 622 Rn NI Sasetisineservesesanaininsniesmmcescesesanstsoeclnesonsssbesnacassienevsnsinaescinniesensiicnaton 920 Minipool screening er IIIs s.ssceconessinlestensdatniiontoexonpuiacsevsatcesisvensetawhinshulisinsedsestebeets 956 HBV DNA Joint arthroplasty, postoperative blood drainage quality K Minor histocompatibility antigens ...............cccccscscssseseseneseseseeeceseeeaeeenees 960 Kell blood group systOM .........:.ssseeseseeseeeeeneeseeeeeeeeeee 545, 969, 1382 Mirasol pathogen reduction technology ................:scsceceseeseseeeeneeeeenenees 920 Kidney biopsy Shhh sa tai cah ai lceb ba ap does cobleaestaiaseaeatiniae 911 Knockout murine transfusion Model .................ccccsesesesessesenesesesecscneneneee 301 Mixed connective tissue disease Knops system antigens, CR1-associated Molecular characterization, of D- individuals .....................c:ccccceeseeeees 3 Ko (Knull) phenotype oO os ciicisvstssiccceiesduantsinisiacaLectentisnaiiincesbiigaianzeaneinaiastoneaiaes 315 Korean persons, D- K’ phenotype, in Swedish population B2 Kuwait 643(L), 1481 Monocyte enrichment ............ ‘ Labeling Monolisa HCV Ag-Ab ULTRA cord blood Mononuclear cell counts ao 4S:189 Mononuclear phagocytes .............scscscssssssssesesescsceseessecseesensscscscececesenencnces 384 1054(E), 1111 Mortality 1349, 1504, 1750 in cardiac surgery 1235(L) 2002 TRANSFUSION Volume 45, December 2005 transfusion-related transplant-related Pall Bacterial Detection System Motivation, for blood donation Pancreatitis, with massive hemolysis Para-Bombay phenotype Multicenter evaluation Paraprotein-associated polyneuropathy of off-label rFVIla use Parasitemia, in donors of Procleix ultrio assay Parasitic-borne infections ... of transcription-mediated assay Parentage, sibling pretenders Multiple sclerosis Parvovirus B19 Multiplex PCR in autologous BMT Multi-step back flush procedure contamination of blood cell preparations/ Mutations products dry-heat inactivation transmission 1003 PAS-27a additive solution JAHK-specific Pathogen-reduction technology missense controlling transfusion-associated risks PLT function Myasthenia gravis .. PLT mitochondrial integrity Myiasis, in donor prestorage pooled PLTs .... riboflavin with UVA NAT. See Nucleic acid testing National Blood Foundation grant recipients PBMNCs, source of research funding PBPCs Scientific Research Grants Program, history collection, low yields Needle puncture for blood donation, arteriovenous mobilization/collection, for amyloidosis . fistula after PBPCT, allogeneic Neoantigens ABO-mismatched Neonatal alloimmune neutropenia, anti-HNA- 1c alloantibodies after Neonatal alloimmune thrombocytopenia HLA match and Netherlands, blood donors IV magnesium supplementation Neuroendocrine sympathoadrenal precursors with major ABO mismatch Neurology, IVIG use in Neutrophil collection Neutrophil donors, glucocorticoid stimulation 722 Neutrophil engraftment Dombrock blood group assay Neutrophil mobilization weer, 604 PCR inhibition assay, for PCT Neutrophil priming, TRALI and .. .. 28:109 Pegylation, thiolation-mediated . NIH public access policy .. 1700(E) PeliCheck reference panels .............00000 sesasnounqepesneahnegnenasncneecsenesentien NK cells Percutaneous coronary interventions, decreasing ischemic Non-transferrin-bound iron complications Normovolemic hemodilution, acute Percutaneous mechanical thromboectomy, hemolysis Nuclear cells during Nucleic acid testing .. Peripheral blood HPC harvest, bacterial contamination amplification... antenatal Phage display technology for bioterror agents Phagyocytosis, FcyR-mediated Phenotypes 994, 1518, 1965 254, 492, 1106 rapid, in resource-poor settings .. blood groupA . sensitivity TOT. meeceosece WNYV. See West Nile Virus NAT H-deficient Nucleocapsid proteins pH meter, for bacterial screening Phosphatidylserine Obituary Photochemical inactivation Kruskall, Margot efficacy, PCR inhibition assay of Oberman, Harold Austen ... van Loghem, J.J. ........--+- HTLV-I and HTLV-II Off-label rFVIla use INTERCEPT Blood System O phenotype Leishmania Optipress II method PLT concentrate OrbiSac system TP photosensitizer for Oriental blood donor population, D antigen . PH testing Orthopedic surgery, postoperative infection .... PLT medium Orthopoxviruses as PLT quality indicator .. Oxaliplatin-induced immune pancytopenia of single-donor PLTs Oxygen, in globin-chain switching Physician, blood bank Oxygen consumption, bacterial contamination detection Placental elution Volume 45, December 2005 TRANSFUSION 2003 SUBJECT INDEX Plasma Platelet-specific antibodies amotosalen interactions Platelet-specific antigens amotosalen photochemical inactivation HTLV-I Platelet storage and HTLV-II bacterial detection citrated DEHP exposure iatrogenic green freeze-thaw process from leukodepleted whole blood prestorage pooling quality from automated apheresis removal of supernatant solution solvent/detergent Platelet storage medium Plasma exchange Platelet substitutes morphine overdose in sickle cell patient Platelet target Platelet transfusion Plasmapheresis, for EPP . anti-D immunization risk . Plasma volume DEHP exposure Plasmodium falciparum malaria, vaccine development . HLA alloimmunization detection by flow cytometry .. «. 1399(L) Plasticity of erythropoiesis prophylactic . 1064, 1523 Plasticizer refractoriness Platelet activation 904, 1349, 1750 risk reduction Platelet additive solutions 743, 927, 1349 threshold Platelet aggregation, in vitro in thrombotic thrombocytopenic purpura Platelet alloantigen Platelet transfusion-associated viral disease Platelet alloimmunization Platelet viability, storage temperature and Platelet antigens PMN donors, posterior subcapsular cataract risk 1697(E), 1701 Platelet collection devices, quality control PMNs indicator for activity after storage Platelet concentrate 420, 1459, 1504 IgM cytotoxic activity against 115-116(L) bacteria contamination detection 265, 731, 984, 1138 Polyethylene glycol 374, 694 buffy coat-derived pooled, automated Polymorphisms 698, 1934 systems for double-unit RIMINI: skicsiriaicisisn dcaiegesansinianinsclebeticansscnaaiseiesnindindabiii hyperconcentrated vs. standard . Porcine parvovirus, dry-heat sensitivity 1692(L) mitochondrial function in Porcine RBCs 1035(L) non-transferrin-bound iron . Posterior subcapsular cataract, risk in PMN donors 1697(E), 1701 residual tissue factor in Postoperative blood loss single-unit Postoperative chronic wounds, frozen-and-thawed storage, transient metabolic suppression for allogeneic platelet gels for virus inactivation Postoperative infection, after WBC-filtered blood volume-reduced components WBC-reduced split apheresis for pediatric use Potassium, extracellular Platelet concentrates amotosalen interactions Prediction method amotosalen photochemical inactivation of bleeding during invasive diagnostic procedures HTLV-I and HTLV-II or blood donor arrival bacterial contamination detection Predonation screening 1518, 1853, 1965 bacteriologic screening for anemia correlation of morphology with recovery and survival for bioterror agents 290(E), 399 engraftment 1037(L) function, storage temperature and 1552(E) leukoreduced, stored in CLX containers... with rapid tests, in resource-poor settings pathogen inactivation in resource-restricted settings 130(E) pathogen reduction methods .... for T.cruzi, sensitivity/specificity Of 0.0.0.0... seeseeseeeeee DO4554 pH meter for bacterial screening . for West Nile virus 460(E), 487 pooled buffy coat Predonation testing, in resource-restricted settings 1541(L), 1542(L) prestorage pooling .. Pregnancy quality assessment anti-Cr’ ... mn radiolabeled JK* immunization reticulated Preoperative autologous blood donation viability assessment Presbyterian Hb Platelet derivatives, tissue regeneration Prestorage pooling Platelet-derived growth factor Prion protein sachtuni 504 Platelet glycoprotein, helper T-cell response Prion removal 1836, 1839 Platelet glycoprotein IIB/IIIA receptor antagonists Probability estimation, of adverse event from blood Platelet mitochondria donation Platelet morphology Procleix ultrio HIV-1 and HCV assay, validation Plateletpheresis Procleix WNV assay 1540(L) growth factor release . Procoagulant activity ..................-cscccsscscsceceresecessssssesecerececesees catavinitonahienet 57. processing time Programmed cell death. See Apoptosis WBC-reduced split apheresis for pediatric use Propidium iodide yields Prosorba column Plateletpheresis machines, randomized crossover trial. ... Prostaglandin E, Platelet pools Protective immunity, in malaria vaccine development Platelet resuspension, plasma vs. saline Protein C, in twice-frozen plasma Platelet-rich plasma Protein S, in twice-frozen plasma 2004 TRANSFUSION Volume 45, December 2005 Recovery of hemopoietic cells Proteomic analysis, RBC supernatants Recruitment Prothrombin time, prolonged Red cell antibodies, hemolytic transfusion reactions P-selectin Red cell indexes, rapid identification of iron deficiency in Pulmonary sequestration, animal models Pure red cell aplasia Red cell volume Purification, SARS hyperimmune globulin .. Reduced-intensity conditioning regimen Reference DNA PVC plastic bags Regenerative stem cell therapy Regional blood centers Renal carcinoma cells Quality control 73 Research pumHb ifloirc aalp hecroersdi sb loPUoTdS st.eccmcs ceccceslclecse sesesoscsseesserscosnsnenssnsssnenanensasocsooes 826, 832 NnBewF cfeulnlduilanrg therapies, administrative policies for Quality markers Resource allocation Quantification Resource-restricted settings HLA-la alleviating blood shortages .....---+---+--+s+sss . 130(E), 1541(L), 1542(L) rapid, anti-A/B predonation testing . RPs after PLT transfusion Reticulated platelets Quantitative assay rFVIla, off-label use RH53 antigen, molecular basis Rh blood group system Race anti-D immunization risk molecular characterization ofD -individuals ethnic variability of locus probability of donor reaction and influence of differences in PBPCT RH locus variability protein functions RADAR repository RHCE gene Radiolabeling RHce mutation Randomized controlled trials _... RHD alleles IVIG use in neurology .. RHD blood group, alleles landmark RHD gene SPRINT trial RHD genotyping Rapid tests RHD zygosity anti-A/B quantification Rhesus box for donor screening in resource-poor settings Rhesus box polymorphism ghfeoirng ohit-ryotpnh irndoeguf gihcpiuetnc yD NiAn doANnAoLrYsS IS ...--.--s-eseeeeseneeneeneeees RRRhHh, o,.plnto ecsurysyn -dvarasrosimoacbeii laittey d Membrane antigen .........------s-seeeneserensenennenneees a‘ RRBBCC aagpglalsuitai nation, in vivo in small child rHu-EPfoOr autologous blood donation 820(L), 821(L) RBC components, white particulate matter formation for hemolytic disease of newborn RBC concentrate, hemolysis reduction in rHuG-CSF, for anti- HNA-Ic neonatal alloimmune eet 1308 RRBBCC ddeepsltertucitoino n, prevention . RibMoEfUlLaTviOnP,E MwIiAt h .U..V-.A.0 0ecervneseoeererennsnnsesencennnnnnnsssnsnnnnnnenssseeesesennets6e 431(3L35),, 11745801 RRBBCC eenxgcrhaafntgmee ntt,ra ndseflusaiyoend, EPP and RRiNtAu xidmetaebc tion, WNV assay 97, 480 RBC genotyping RNA interference RBC glycerolization, Closed-system . RRRBBBCCC impnhedemenxboersta,y npeei,n bpplrooorotcdei inndeso no..r. s 1c0oe3 5S(OL)D Bce-xo1pm9rp-eassprseeicodin f iwcoi ft hiK neflBelca tcbiTlvoi/toAydL EagsRrsToa uy ps ysptreotme ins ........------ FRIIS .acescosooncsosecsecsssveoresesserensneonenvansnnosaconsnsssssceresewenenne for orthopoxviruses leukoreduced, for cardiac surgery RH locus variability low-affinity Hb-containing for endotoxemia percentage of hypochromatic mature, rapid identification of radiolabeled Safety RBC sstuorrvaigvea l . 822(L), 823(L) bcloomopdu tseerr viscoelsu tnieontsw ortok reduce errors protein accumulation, 1426 photochemically-treated PLTs RBC sTtPo rapgheo tloesseinosnist izer and DP 1426, 1496 Saline,§ -f3o0r3 flRuBidC sr esuscitation vs. albumin ... RBC supernatants, proteomic analysis SARS, hyperimmune globulin purification RBC suspensions, after irradiation and washing, SARS-Hcov, viral inactivation extracellular K+ in RBC transfusions Scansystem method complications long-term Scianna blood group tranexamic acid reduces requirements after TKA Semiautomated system, for RBC depletion RCC, prion removal Sensitivity RealArt™ Orthopox LC PCR kit . of BacT/ALERT culture system Recombinant antigens of enhanced bacterial detection system .... Recombinant factor Vila, in cardiac surgery... HCV NAT Recovered plasma Volume 45, December 2005 TRANSFUSION 2005 SUBJECT INDEX noninvasive Hb screening Thrombotic thrombocytopenic purpura plasma exchange for ... - 1453, 1523 PH testing of single-donor apheresis platelets plasma infusion for of WNV Nucleic acid testing platelet transfusion Sensitivity, of nucleic acid amplification tests . vincristine with plasma exchange for low-affinity Hb-containing RBCs for Thromboxane A2 posttransfusion Tissue factor Septic shock, posttransfusion . Tissue regeneration, PLT-induced .... Serologic tests TNC count, cord blood unit quality Dombrock blood group system Total knee arthroplasty placental elute Toxoplasma gondii antibodies 281-282(L) Rh,un Syndrome 28:109, 1042(L), 1628 Tranexamic acid of donor, white particulate matter (WPM) formation in RBC Transcription-mediated amplification assay ... . 994, 1988 components Transforming growth factors .. 28:51, 414 hematopoietic progenitor cell content in cord blood Transfusion-associated adverse pulmonary sequelae 1048(E) of newborn CD34+ cord blood content and Transfusion-associated circulatory overload probability of donor reaction and Transfusion history, HBV and HCV risk Transfusion immunomodulation Short tandem repeat i Transfusion lookback program, HCV Sibling pretenders, to parentage .. ... 440 Transfusion medicine Sickle cell disease 825(E) advancing, strategies for Signal-to-cutoff ratios, for HCV EIA clinical trials network Simian adenovirus 15, viral inactivation historical review Single-nucleotide polymorphism as profession Solid-phase red cell adherence system Transfusion providers Solvent/detergent plasma Transfusion reaction, hyperhemolysis syndrome Spanish population, Wr* antigen and anti-Wr' in Transfusion-related acute lung injury Specificity, noninvasive Hb screening (TRALI) Spinal surgery, pediatric Transfusions. See also specific types of transfusions Spleen, in immune thrombocytopenia clinical trial regulations SPRINT trial requirements, clinical endpoints Transfusion-transmitted infections. See also specific infections Staphylococcal protein A immunomodulation cord blood testing Staphylococcus epidermidis STAR antigen in Italy Stem cell therapy male-to-male sexual experience on donor risk profile Storage reducing by NAT cord blood transfusion history . liquid [VIG viral, prevalence of platelet activation during Transmissibility by transfusion, donor-recipient repository PLT viability assessment Transportation room temperature TRAP study stress-enhanced PLT storage lesions . Trauma temperature AU NNN IN isc scscnseveieseccesinsvcsnenscscininusinnntinninctcnnnh 18:14 WBC-reduced split apheresis PLT concentrates fluid resuscitation we 18:4 white particulate matter (WPM) formation in RBC posttransfusion microchimerism components Trehalose Storage containers, leukoreduced platelets TRICC trial Triglycerides, WPM formation in RBC components STR typing Trima Accel plateletpheresis device Surface plasmon resonance method, anti-A/B quantification. ... Trima v4 apheresis platform Surgery, postoperative blood drainage quality Trypan blue exclusion staining Survival, fetal RBCs 1985(L) BRINN cirtcincssccsnvavcastnnceseseciensenduepesaninninininianininssteeiciaiiapeavaghe S Swedish population, K° phenotype it ..............cccccccesesesneeneseeesneeenceeees 545 T-Sol additive solution Umbilical cord blood. See Cord blood TaqMan 5’ nuclease assay United States T-cell responses blood collection and transfusion in Tetragametic chimerism CURRIE I IIIS i csccnsevccscecnssensssnacciesensessnespsncoraacvanvcivans 18:14 Thalassemia HHV-8 transmission via blood transfusion ...................c0seeee00+ 500 Theory of Planned Behavior ................ccscsessesessesssseseeseseesesesneseencacenencenene 945 PLT preparation Therapeutic plasma exchange. See Plasma exch.inge West Nile virus epidemic of 2003 Thimerosal Universal leukoreduction Th1 immunity UVA irradiation Thiol-disulifide groups Thiopyrylium photosensitizer Thrombocytcpenia 2006 TRANSFUSION Volume 45, December 2005